TME PHARMA NV (ALTME.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALTME - NL0015000YE1 - Common Stock
ALTME.PA Key Statistics, Chart & Performance
The current stock price of ALTME.PA is 0.0665 EUR. In the past month the price increased by 2.31%. In the past year, price decreased by -7.25%.
ALTME.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.09 | 44.23B | ||
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.21B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.83B | ||
| NANO.PA | NANOBIOTIX | N/A | 954.18M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 705.43M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About ALTME.PA
Company Profile
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
Company Info
TME PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 13
Phone: 49307262470
TME PHARMA NV / ALTME.PA FAQ
What does TME PHARMA NV do?
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
Can you provide the latest stock price for TME PHARMA NV?
The current stock price of ALTME.PA is 0.0665 EUR. The price decreased by -0.45% in the last trading session.
Does ALTME stock pay dividends?
ALTME.PA does not pay a dividend.
How is the ChartMill rating for TME PHARMA NV?
ALTME.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the expected growth for ALTME stock?
The Revenue of TME PHARMA NV (ALTME.PA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for TME PHARMA NV?
TME PHARMA NV (ALTME.PA) has a market capitalization of 6.26M EUR. This makes ALTME.PA a Nano Cap stock.
ALTME.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALTME.PA. When comparing the yearly performance of all stocks, ALTME.PA is a bad performer in the overall market: 91.3% of all stocks are doing better.
ALTME.PA Financial Highlights
Over the last trailing twelve months ALTME.PA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 86.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -199.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALTME.PA Forecast & Estimates
9 analysts have analysed ALTME.PA and the average price target is 0.36 EUR. This implies a price increase of 446.81% is expected in the next year compared to the current price of 0.0665.
For the next year, analysts expect an EPS growth of 89.47% and a revenue growth -100% for ALTME.PA